InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Vaccine Contract Manufacturing Market - (By Vaccine Type (Attenuated, Inactivated, Subunit-based, Toxoid-based, DNA-based), By Type of Expression System (Avian Expression Systems, Bacterial Expression Systems, Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs), Insect Expression Systems, Mammalian Expression Systems, Plant Expression Systems, Yeast Expression Systems), By Workflow (Downstream, Upstream), By Application (Human Use, Veterinary)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global Vaccine Contract Manufacturing Market is valued at USD 2.3 Bn in 2024, and it is expected to reach USD 3.9 Bn by the year 2034 , with a CAGR of 6.0% during the forecast period of 2025-2034.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2303
Vaccine contract manufacturing refers to the outsourcing of vaccine production to specialized external manufacturers, known as Contract Manufacturing Organizations (CMOs) or Contract Development and Manufacturing Organizations (CDMOs). This approach allows vaccine developers and pharmaceutical companies to leverage the expertise, infrastructure, and technical capabilities of specialized manufacturing partners to produce vaccines efficiently and at scale.
The growth of the vaccine contract manufacturing market is primarily driven by a combination of global health priorities, technological advancements, strategic industry initiatives, and the increasing need for flexible and scalable production solutions. Improvements in manufacturing technology and cost efficiencies in infrastructure and operations, along with supportive vaccination programs, favorable patient demographics, and increasing immunization rates among infants and children, are significantly contributing to market expansion. Furthermore, a global increase in research and development activities, coupled with clinical trials aimed at accelerating the development of safe and effective vaccines, has heightened vaccine demand and strengthened production capacity, thereby driving market growth. The rising demand for vaccines has also prompted increased investments in manufacturing and clinical trial infrastructure. Additionally, the market is expected to benefit from various government and health organization initiatives focused on expanding vaccination access and coverage worldwide.
List of Prominent Players in the Vaccine Contract Manufacturing Market:
• Lonza
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Ajinomoto Althea, Inc.
• Merck KgaA
• Cytovance Biologics
• Catalent, Inc.
• IDT Biologika GmbH
• Albany Molecular Research, Inc.
• PRA Health Sciences
• ICON plc.
• Pharmaceutical Product Development, LLC
• Cobra Bio
• Paragon Bioservices, Inc.
• Charles River Laboratories
• Meridian Life Science (MLS)
• Eurogentec
• GreenPak Biotech
• Hong Kong Institute of Biotechnology
• WuXi Biologics
• Bharat Biotech
• Biological E
• Others
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market Dynamics
Drivers
The increasing demand for efficient and scalable vaccine manufacturing technologies is driven by the global focus on expanding vaccine distribution, particularly in response to infectious diseases and public health emergencies. Contract Manufacturing Organizations (CMOs) play a pivotal role in this environment due to their expertise and infrastructure, enabling them to meet the growing demands of vaccine production. Advances in vaccine technology, including innovations in genetic engineering, vaccine delivery systems, and proteomics, are further transforming the industry's landscape. Additionally, the anticipated market expansion is supported by strategic initiatives from key industry players, such as business expansions, partnerships, and acquisitions. The rising global demand for vaccine contract manufacturing is expected to significantly drive market growth.
Challenges
Several factors may hinder the growth of the vaccine contract manufacturing market during the forecast period. These include the rising costs of vaccine production and the lack of adequate storage infrastructure. Ensuring consistent vaccine quality remains a critical challenge due to vaccines' essential role in public health. Any deviation from established quality standards could lead to product recalls, regulatory penalties, and reputational damage for CMOs. Maintaining high safety and efficacy standards requires stringent oversight and continuous investment in quality assurance processes, which can be both resource-intensive and time-consuming. Additionally, the vaccine supply chain remains vulnerable to various risks, including shortages of critical raw materials, disruptions in transportation networks, and unforeseen global events such as pandemics and geopolitical tensions. These challenges can result in production and distribution delays, limiting CMOs’ ability to meet growing market demands.
Regional Trends
The North American vaccine contract manufacturing market is expected to capture a significant market share. The region’s growth is supported by the increasing adoption of advanced manufacturing techniques and notable technological progress in vaccine research and development. Furthermore, a population highly aware of vaccine availability further contributes to the region’s market strength. Meanwhile, the Asia-Pacific region holds a considerable market share, supported by a well-established pharmaceutical and biotechnology sector that offers cost-effective manufacturing solutions for global vaccine developers. The region also benefits from a skilled workforce and advanced manufacturing infrastructure, reinforcing its position as a key player in the global market.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2303
Recent Developments:
• In Oct 2023, Vaxcyte, Inc. and Lonza have recently established a fresh commercial production arrangement. This partnership further facilitates the eventual worldwide commercialization of Vaxcyte's PCV candidates, VAX-24 and VAX-31, in both adults and children. This arrangement enhances Vaxcyte's strategy to leverage Lonza's existing infrastructure for the purpose of accelerating clinical development and facilitating the expected initial introduction of VAX-24 for the adult demographic in the United States.
• In March 2021, Catalent has enhanced its collaboration with Johnson & Johnson to substantially augment the capability for sterile production and packaging of the COVID-19 vaccine in Italy. Catalent and Janssen had already reached an agreement to allocate an already existing vial-filling line at the Anagni factory.
Segmentation of Vaccine Contract Manufacturing Market-
By Vaccine Type
• Attenuated
• Inactivated
• Subunit-based
• Toxoid-based
• DNA-based
By Type of Expression System
• Avian Expression Systems
• Bacterial Expression Systems
• Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
• Insect Expression Systems
• Mammalian Expression Systems
• Plant Expression Systems
• Yeast Expression Systems
By Workflow
• Downstream
• Upstream
By Application
• Human Use
• Veterinary
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2303
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.